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Gram-negative bacterial molecules
associate with Alzheimer disease pathology
ABSTRACT
Objective: We determined whether Gram-negative bacterial molecules are associated with
Alzheimer disease (AD) neuropathology given that previous studies demonstrate Gram-
negative Escherichia coli bacteria can form extracellular amyloid and Gram-negative bacteria
have been reported as the predominant bacteria found in normal human brains.
Methods: Brain samples from gray and white matter were studied from patients with AD (n 5 24)
and age-matched controls (n 5 18). Lipopolysaccharide (LPS) and E coli K99 pili protein were
evaluated byWestern blots and immunocytochemistry. Human brain samples were assessed for E
coli DNA followed by DNA sequencing.
Results: LPS and E coli K99 were detected immunocytochemically in brain parenchyma and
vessels in all AD and control brains. K99 levels measured using Western blots were greater in
AD compared to control brains (p, 0.01) and K99 was localized to neuron-like cells in AD but not
control brains. LPS levels were also greater in AD compared to control brain. LPS colocalized with
Ab1-40/42 in amyloid plaques and with Ab1-40/42 around vessels in AD brains. DNA sequencing
confirmed E coli DNA in human control and AD brains.
Conclusions: E coli K99 and LPS levels were greater in AD compared to control brains. LPS
colocalized with Ab1-40/42 in amyloid plaques and around vessels in AD brain. The data show
that Gram-negative bacterial molecules are associated with AD neuropathology. They are con-
sistent with our LPS-ischemia-hypoxia rat model that produces myelin aggregates that colocalize
with Ab and resemble amyloid-like plaques. Neurology® 2016;87:2324–2332
GLOSSARY
AD 5 Alzheimer disease; CERAD 5 Consortium to Establish a Registry for Alzheimer’s Disease; DAPI 5 4’,6-diamidino-2-
phenylindole; GM 5 gray matter; IL 5 interleukin; LPS 5 lipopolysaccharide; NSAID 5 nonsteroidal anti-inflammatory drug;
WM 5 white matter.
Although age is the primary risk factor for the late-onset sporadic form of Alzheimer disease
(AD), infection has also been implicated.1 Infection increases the odds of developing AD by
2-fold over 5 years.2 Diphtheria, tetanus, and pertussis; polio; tetanus; and influenza vaccines
reduce the risk of subsequent AD.3,4 Inflammatory molecules including C-reactive protein and
inerleukin-6 are elevated in blood years before dementia.5,6 Though clinical trials show that
nonsteroidal anti-inflammatory drugs (NSAIDs) do not affect cognitive decline in AD,7 some
studies suggest that NSAIDs decrease the risk of developing AD.8 Indeed, recent studies have
demonstrated that sporadic late-onset AD is associated with infections.9–12 However, a consistent
link between these agents and AD neuropathology has not been demonstrated.
Gram-negative bacteria like Escherichia coli can deposit amyloid.13,14 Moreover, we showed
that administration of Gram-negative bacteria–derived lipopolysaccharide (LPS) followed by
ischemia-hypoxia produce plaque-like aggregates of b-amyloid in rat brains.15 Though Gram-
negative bacteria have been reported as the predominant bacteria found in normal human
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brains,16 the study did not describe pathologic
correlates. Because of our finding that LPS
promoted formation of amyloid-like plaques
in rat brain,15 we determined whether Gram-
negative bacterial molecules were associated
with human AD neuropathology.
METHODS Standard protocol approvals, registrations,
and patient consents. The institutional review board approved
this study. Informed consent was obtained from all participants
who were enrolled in studies at the University of California at Da-
vis Alzheimer’s Disease Center.
Brain samples. AD was rated using Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD) criteria and Braak
stage on 24 AD and 18 age-matched controls. Brain tissue was
provided by the Alzheimer’s Disease Center at the University of
California Davis. Superior temporal gyrus gray matter (GM) was
studied since it is commonly involved in AD and frontal lobe white
matter (WM) was studied because it shows abnormalities in AD
brains.17 Controls were age-matched individuals without cognitive
deficits. Formalin-fixed brains used for immunostaining included
11 AD and 7 age-matched controls. Frozen brains used forWestern
blot analysis and PCR for E coliDNA included 13 AD and 11 age-
matched controls.
Frozen tissue (;1 cm3) from the superior temporal gyrus GM
or frontal lobe WM was removed with sterile technique and
frozen at 2708C. The tissue surface was treated with 75% eth-
anol and removed with a sterile scalpel blade. Frozen tissue was
cored with autoclaved trephines and placed in sterile, endotoxin-
free tubes at 2708C. Formalin-fixed (4%) brains were blocked,
embedded in paraffin, and sectioned for immunostaining.
Immunofluorescence. Detailed methods are described in our
previous studies.15,17,18 Briefly, after removing paraffin with
xylene and rehydrating through graded alcohols, sections were
treated with antigen retrieval buffer and autofluorescence elimi-
nator reagent (Millipore, Etobicoke, Canada). Primary antibodies
were used in 1:200 concentrations unless stated otherwise. Sec-
ondary antibodies included either goat anti-mouse or goat anti-
rabbit Alexa Fluor 488 or 594 (Invitrogen, Carlsbad, CA). Slide
mounting medium included 4’,6-diamidino-2-phenylindole
(DAPI) to stain nuclei (Vector Laboratories, Burlingame, CA).
For controls, primary antibody was deleted or immunodepleted
with the target antigen of the antibody.
Western blot analysis. Tissue was homogenized in cold RIPA
buffer containing a protease inhibitor mixture. After centrifuging
homogenates for 30 minutes at 48C (14,000 g), the pellet was
discarded and proteins in the supernatant separated on 10%
sodium dodecyl sulfate polyacrylamide gels. They were then trans-
ferred to nitrocellulose membranes and hybridized overnight at 48C
with primary antibodies listed below. Antibodies were stained using
horseradish peroxidase conjugated anti-rabbit or anti-mouse
immunoglobulin G (Bio-Rad, Hercules, CA) combined with
electrochemiluminescence detection (Piers). b-actin staining
served as the control. We used NIH Image J software to quantify
band intensities.
Primary antibodies were obtained from Abbiotec (San Diego,
CA) (glial fibrillary acid protein, 250661; MAG, 250744),
Abcam (Cambridge, UK) (E coli LPS, ab35654), Lifespan (Prov-
idence, RI) (E coli K99, LS-C83195), Millipore (Ab1-40/42,
AB5076; NeuN, ABN2300A4; NG2, AB5320), RayBiotech
(Norcross, GA) (E coli LPS, MD-05-0148), Santa Cruz
Biotechnology (Dallas, TX) (b-actin, sc-69879), ThermoFisher
(Waltham, MA) (GSTp, PA529601; Synapsin 2, OSS00020W),
and Wako Chemicals (Cape Charles, VA) (Iba1, 019–19741).
PCR for DNA and DNA sequencing. E coli DNA was de-
tected using PCR amplification of an E coli glutamate decarbox-
ylase B (gadB) DNA fragment.19 This DNA fragment was
selected because it detects all E coli strains, and does not detect
the human gene.19 All reagents used for PCR were first tested for
E coli DNA contamination, which was indicated by detection of
E coli DNA in endotoxin free water. Only those reagents that
were free of E coli DNA were used for PCR amplification in
human brains. Brain genomic DNA samples were isolated and
purified using PureLink Genomic DNA Kits (K1820-01, Life
Technologies, Carlsbad, CA). Approximately 20 mg of minced
brain tissue from superior temporal gyrus was digested and DNA
was eluted and frozen. E coli DNA from the ATCC 8739 strain
(ATCC) was used as a positive control. PCR amplification was
performed in a 50 mL reaction mixture, containing 10 ng of
DNA, 25 mL of 2 3 GoTaq Colorless Master Mix (Promega,
Madison, WI), and 0.5 mM primer mix. The reaction mixtures
were placed in a Gene Amp PCR System 9700 (Applied Biosys-
tems, Foster City, CA) with the following settings: 5 minutes at
948C, followed by 38 cycles of 40 seconds at 948C, 45 seconds at
578C, 30 seconds at 728C, and a final extension time of 7 minutes
at 728C. Amplified products were analyzed in an Agilent (Santa
Clara, CA) 2100 Bioanalyzer. Identification of the gadB gene was
confirmed by a 39 and 59 Sanger DNA sequencing assay on 3
control and 3 AD samples at the UC Davis DNA Sequencing
Facility. PCR products were sequenced with BigDye Terminator
v 3.1 Cycle Sequencing Kit with Gel Company Better Buffer and
postcycle sequencing purification was achieved at a Beckman
Coulter (Sharon Hill, PA) Biomek NXp laboratory automation
workstation with Beckman-Coulter CleanSEQ magnetic bead
purification. Data were analyzed with ABI Prism (Applied
Biosystems) 3730 genetic analyzer, ABI Prism 3730 data
collection software v 3.0, and ABI Prism DNA sequencing
analysis software v 5.2. DNA primers used in this study for PCR
amplification and DNA sequencing were forward sequence
(59/39) CACGTTTTGGTGCGAAGTCT and reverse
sequence (59/39) TTGTGGACATTTTCGTCGTC (Eurofins
MWG, Huntsville, AL). Amplicons were 175 bp with amplicon
accession number M84025.1.19
Statistical analysis. Differences between groups were analyzed
using a Student t test (continuous), Wilcoxon–Mann-Whitney
test (ordinal), or Fisher exact test (categorical). Differences
between multiple groups were analyzed using one-way analysis of
variance with Student-Newman-Keuls post hoc test. A p , 0.05
was considered significant.
RESULTS Patient characteristics. There were no sig-
nificant differences in age or sex between patients
with AD and controls (table e-1 at Neurology.org).
The differences in median Braak and Braak stage20
and CERAD plaque scores between AD and control
brains were significant (table e-1).
Detection of E coli K99 and Gram-negative bacterial LPS
in AD and control brains. Control samples (n 5 10)
and AD samples (n 5 13) including GM (figure 1A)
and WM (figure 1B) were assessed for E coli K99 pili
protein.21 K99 was present in 9/13 AD GM com-
pared to 1/10 control GM samples (p 5 0.006)
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and in 10/13 AD WM compared to 4/10 control
WM samples (p 5 0.09). Quantification showed sig-
nificantly greater amounts of E coli K99 protein in
AD GM compared to controls and significantly more
K99 in AD WM compared to controls (figure 1C).
In addition, we used Western blots to test the
specificity of Gram-negative LPS antibody, which
was used for the immunocytochemistry studies
described below. The LPS Western blots using the
Abcam antibody (figure 1D, upper panel) showed
a similar pattern of expression as that seen for the
K99 Western blots (figure 1D, lower panel). LPS
(Abcam antibody) was detected by Western blots in
3/3 AD GM, 3/3 AD WM, and 0/3 control GM (fig-
ure 1D). As a control, we repeated the Western blots of
AD brain using another antibody to LPS (RayBiotech)
as well as doing a blot after immunoprecipitating the
antibody with LPS. The RayBiotech anti-LPS anti-
body detected a large band at 37 kD and a smaller
band at 150 kD (figure e-1), whereas the LPS
Figure 1 Western blot analysis of Escherichia coli K99 pili protein and Gram-negative bacterial
lipopolysaccharide (LPS) in human brains
(A) Western blot analysis of E coli K99 pili protein in gray matter (GM). E coli K99 was detected in 9 out of 13 Alzheimer
disease (AD) cases and 1 out of 10 control (C) cases. (B) Western blot analysis of E coli K99 pili protein in white matter (WM).
E coli K99 was detected in 10 out of 13 AD cases and 4 out of 10 control cases. (C) Quantification of E coli K99 protein. E
coli K99 protein levels in AD brains were greater than in control aged brains in both GM (*p, 0.05) andWM (**p, 0.01). (D)
Western blot analysis of Gram-negative bacterial LPS. A total of 3/3 AD GM, 3/3 ADWM, and 0/3 control GM showed LPS.
Error bars are standard errors of the mean. b-actin was used as a loading control.
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immunodepleted antibody showed the 150 kD band
only with complete loss of the 37 kD band (figure e-
1). This is strong evidence the antibody detects LPS in
the 37 kD band, and this is the same molecular weight
as the 37 kD large band seen in figure 1D with the
Abcam anti-LPS antibody (upper panel).
Localization of LPS and K99 pili protein in cells in AD
and control brains. E coli LPS (Abcam antibody) and
K99 pili protein were detected immunocytochemi-
cally in all 11 AD and 7 control brains. LPS was
detected in control (figure 2, A and C) and AD brains
(figure 2, B and D) in GM (figure 2, A and B) and in
periventricular WM (figure 2, C and D). For a con-
trol, coimmunoprecipitation of the anti-LPS
antibody with LPS completely eliminated all tissue
staining by immunofluorescence (figure e-2) or by
immunohistochemistry (figure e-3), showing that
LPS was being immunostained.
LPS was localized in neurons (figures e-4 and
e-5), microglia (figure e-6), oligodendrocytes, and
oligodendrocyte progenitor cells (figures e-7
and e-8). LPS colocalized with a nuclear marker,
DAPI, in control GM (figure 2E) and WM (figure
2G) including ependymal cells (figure 2G, arrow-
heads). In AD GM there was LPS staining in what
appeared to be amyloid plaques in cortex (figure 2, B
and F, white arrow). Smaller LPS-stained structures
appeared to be nuclei in GM (figure 2, B and F,
yellow arrowheads) and WM (figure 2, D and H).
Note that ependymal cells were missing in AD brain
(figure 2H, arrowheads) and DAPI was absent in
many nuclei that were stained with LPS in WM
(figure 2H).
K99 pili protein was associated with neuron-like
cells in AD cortex (figure 3B) but not in controls
(figure 3A). K99 pili protein was localized to control
ependymal cells (figure 3C) that were lost in AD
brains (figure 3D, arrowheads). K99 pili protein im-
munostaining of fiber tracts in AD WM (figure 3D)
was greater than in controls (figure 3C).
Association of LPS with amyloid plaques in AD brains.
LPS positively stained clusters were frequently
observed in AD brains (figure e-9, A1, arrow). Within
these clusters, DNA stained with DAPI from
coalesced cells and was indistinct (figure e-9, A2
and A3, arrows). Moreover, the coalesced DNA colo-
calized with Ab1-40/42 (figure e-9, B1-3, arrows).
LPS and Ab1-40/42 colocalized in 3 different pat-
terns in AD brains. (1) Clusters composed mainly of
LPS particles colocalized with Ab1-40/42 (figure 4A).
(2) Ab1-40/42 deposits that colocalized with LPS were
surrounded by LPS (figure 4, B and C). (3) The most
common pattern showed confluent Ab1-40/42 stained
amyloid plaques with scattered LPS particles in them
(figure 4D).
LPS-stained plaques were surrounded by astro-
cytes (figure e-10, B1-4, arrows). In AD cortex,
LPS was localized in neurons, microglia, oligodendro-
cytes, and oligodendrocyte progenitor cells (B1-B4,
figures e-4 through e-8).
In contrast, K99 pili protein surrounded small
Ab1-40/42 stained amyloid plaques (figure 4, E–G),
but was absent around larger amyloid plaques
(diameter .50 mm) (figure 4H).
Association of LPS and K99 pili protein with blood
vessels. In control brains, both LPS (figure 5A) and E
coli K99 (figure 5C) localized to blood vessels that did
not stain for Ab1-40/42 (figure 5, A and C). In con-
trast, LPS and Ab1-40/42 colocalized in vessel walls of
AD brains (yellow staining, figure 5B). Ab1-40/42 was
sandwiched by but did not colocalize with K99 pili
protein in vessels in AD brains (figure 5D,
arrowheads).
E coliDNA in AD and control brains. PCR with primers
for the E coli glutamate decarboxylase B gene (gadB)19
showed the predicted 175 bp DNA fragment, which
was the same size in control and AD GM, as well as in
the positive control ATCC 8739 E coli strain
(figure e-11). The 175 bp amplicon was detected in
9/10 normal control (figure e-11A) and 9/13 AD
brains (figure e-11B). Of these, 1/10 control and
4/13 AD samples showed bands of different sizes
(figure e-11) of unknown significance. All samples
showed low molecular weight bands that likely rep-
resented primer interactions. A megablast (optimized
for highly similar sequences; NCBI nonredundant
nucleotide database) of the DNA sequences
(table e-2) of the amplicons from the qPCR reactions
showed that DNA from the 3 human controls
(table e-2) was 100% identical to 115 E coli strains/
substrains/entries in the database, and to 5 Shigella
strains. The DNA sequence from one of the AD
samples (table e-2) was 100% identical to 7 strains/
substrains/entries of E coli, while the DNA from the
other AD sample (table e-2) had one nucleotide mis-
match from 116 E coli strains/substrains/entries, and
one mismatch (99.4% identity) from the same 5
Shigella strains as the other AD sample. One AD
sample (AD1), negative on quantitative PCR, was
also negative upon sequencing.
DISCUSSION We demonstrate Gram-negative
bacterial LPS, E coli K99 pili protein, and DNA in
control and AD brains. K99 and LPS levels were
greater in AD compared to control brains.
Moreover, LPS colocalized with Ab1-40/42 in
amyloid plaques and with Ab1-40/42 around blood
vessels in AD brains. These data suggest that Gram-
negative bacterial molecules are associated with AD
pathology.
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Though the monoclonal antibodies were raised to
E coli molecules, they may not be specific for E coli.
PCR showed appropriate size bands for E coliDNA in
the majority of AD and control brains. Sequencing
the bands showed that though most 100% identical
hits were for E coli, there were 100% identical hits for
Figure 2 Immunofluorescence of lipopolysaccharide (LPS) in human brains
Immunocytochemistry for LPS showed staining in both control (A, C) and Alzheimer disease (AD) brains (B, D) in gray matter
(GM) (A, B) and in periventricular white matter (PVWM, C, D). LPS colocalized with 4’,6-diamidino-2-phenylindole (DAPI)–
stained nuclei in control GM (E) andWM (G) including ependymal cells (G, arrowheads). The patterns of control LPS staining in
the DAPI-stained nuclei varied (E; yellow, green, and white arrowheads). In AD GM, there were large foci of LPS staining that
appeared to be plaques in cortex (Ctx) (B, F; white arrow), and other LPS-stained structures that appeared to be the size of
nuclei in GM (B, F; yellow arrowheads). LPS staining was detected in control (C, G) and AD (D, H) WM. DAPI staining of nuclei
was decreased in AD Ctx (F) and in WM (H) including ventricular ependymal cells (H, white arrowheads), likely indicating cell
loss. LPS was detected in all 11 AD brains and all 7 control brains by immunofluorescence. Bar 5 25 mm.
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a related Gram-negative family member, Shigella,
which is due to the sequence homology between
the 2 species. Thus, the data support the presence
of proteins and DNA from E coli or Gram-negative
bacteria related to E coli.
Our findings complement a recent RNAseq study
that showed bacterially encoded 16s RNA sequences
in all human brains with Gram-negativea-Proteobacteria
representing over 70% of bacterial sequences.16
The other 30% of bacterial classes varied widely, with
g-Proteobacteria, including E coli, being present at
,5% of total bacterial transcripts found.16 Thus our
data support this previous study.
A major question arises as to how Gram-negative
bacterial LPS, proteins and DNA in this study, and
a-Proteobacteria molecules16 or Gram-positive bac-
terial peptidoglycan22,23 in other studies enter brain.
In our LPS/ischemia/hypoxia animal model, we
showed that LPS increased in rat brain over a period
of 3 months after a single intraperitoneal injection
that was associated with a parallel increase in IL-1b
and granzyme B in brain.15 We postulated
that IL-1b-producing monocytes and granzyme
B–producing cytotoxic T cells or natural killer cells
phagocytized the LPS in the periphery via Toll 4
receptors and carried LPS into brain.15 Gamma
Proteobacteria enterobacteriaceae like E coli, and
related family members like Salmonella and Shigella,
cause diarrheal illness in humans,24 and some strains
of E coli are resident in the gastrointestinal tract. The
virulence of enterotoxigenic E coli that cause diar-
rhea are dependent on production of adhesins and
enterotoxins, and the E coli K99 pili protein found
in control and AD brains is one of the surface an-
tigens in enterotoxigenic (diarrhea) E coli adhesive
pili.25 It is tempting to speculate that this study
provides another example of a gut-to-brain connec-
tion26 with gut being one possible source of brain E
coli supporting the concept of AD being a systemic
disease.27 E coli from urinary tract and other infec-
tions could also be a source for brain bacterial
molecules. Finally, since LPS derived from Gram-
negative bacteria injures the blood–brain barrier,28
this could promote entry of LPS and other bacterial
molecules into the brain.
Previous studies show that sporadic late-onset AD
can be associated with infection.9–12 Infectious agents
previously associated with AD include Spirochetes,
P gingivalis, Borrelia burgdorferi, Chlamydophila
pneumonia, Helicobacter pylori, C glabrata, various
fungi, herpesviruses, and cytomegalovirus.9–12 A
major difference between previous studies and this
Figure 3 Immunofluorescence of Escherichia coli K99 pili protein in human brains
E coli K99 staining in control cortex (Ctx) was punctate and not associated with 4’,6-diamidino-2-phenylindole (DAPI)–
stained nuclei (A). In control white matter, K99 staining appeared to be associated with fiber tracts (C). In Alzheimer dis-
ease (AD) gray matter (GM), E coli K99 pili protein was often found in pyramidal cells in the cytoplasm and not the nucleus (B,
arrowheads). There was intense E coli K99 pili protein staining in AD periventricular white matter (PVWM) (D) with loss of
normal DAPI-stained ependymal cells in AD brains (D, arrowheads) compared to controls (C, arrowheads). E coli K99 pili
protein was detected in all 11 AD brains and all 7 control brains by immunofluorescence. Bar 5 25 mm.
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one is that LPS colocalized with amyloid plaque and
with perivascular amyloid in every AD brain.
LPS is the major component of the outer mem-
brane of Gram-negative bacteria. Gram-negative
bacteria include a-Proteobacteria found in human
brain16 and include g-Proteobacteria like E coli, mol-
ecules of which were found in brain in this study. LPS
was colocalized with Ab1-40/42 in amyloid plaques
Figure 4 Association of lipopolysaccharide (LPS) and Escherichia coli K99 pili protein with amyloid plaques in
Alzheimer disease (AD) brains
There were several different patterns of colocalization of LPS and Ab1-40/42 in AD brains. There were clusters of pre-
dominantly LPS particles that colocalized with Ab1-40/42 (A). There were Ab1-40/42 deposits that colocalized with LPS
and were surrounded by LPS (B, C). Finally, there were confluent Ab1-40/42-stained amyloid plaques that had scattered
LPS particles within them (D). These LPS results contrasted with E coli K99 pili protein, which often surrounded small
Ab1-40/42-stained amyloid plaques (E–G). For larger amyloid plaques (diameter .50 mm), E coli K99 was usually absent (H).
Bar 5 25 mm.
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and with perivascular Ab1-40/42 in all AD brains. In
our recent animal study, systemic LPS combined with
cerebral ischemia/hypoxia produced aggregates of
myelin that colocalized with Ab1-40/42 in adult rat
brains and the aggregates had features of amyloid
plaques.15 These animal data, combined with the cur-
rent human brain data, suggest the possibility that
LPS in combination with other factors could cause
AD neuropathology.
LPS and E coli K99 pili protein in vessels and epen-
dymal cells could contribute to vessel injury29 and
ependymal injury17 and WM injury observed in AD
brains. There was more K99 pili protein in GM and
WM of AD brains, and both WM and GM are con-
sistently damaged in AD.17,30 However, the current
human data cannot determine if the bacterial molecules
are a cause or consequence of the injury to AD brain.
There are limitations to this study. E coli could
contaminate tissue samples. We used sterile techni-
ques, sterile solutions, and sampled the core of frozen
tissue blocks to reduce contamination. Evidence
against E coli contamination includes the finding that
LPS and E coli K99 staining patterns in control and
AD brains were different, the staining patterns were
consistent in all brains, and levels of K99 and LPS
were higher in AD compared to control brains.
Studies of brain biopsies obtained during life would
help address the possibility of contamination during
autopsy, however.
The current study did not test whether there are live
bacteria in human brain. However, a recent study
found evidence for live bacteria in brain and supports
the idea that every organ, including brain, has its own
microbiome.16 Since this study focused on E coli pro-
teins and DNA, future studies will be needed to address
the potential for other bacteria in AD pathogenesis.
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